Peter J Leary1, Nancy S Jenny2, David A Bluemke3, Steven M Kawut4, Richard A Kronmal5, Joao A Lima6, Bradley A Maron7, David D Ralph8, Samuel G Rayner8, John J Ryan9, Zachary L Steinberg8, Karen D Hinckley Stukovsky5, Ryan J Tedford10. 1. University of Washington, Department of Medicine, Seattle, Washington. Electronic address: learyp@uw.edu. 2. University of Vermont, Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont. 3. University of Wisconsin, Department of Radiology. 4. Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Department of Biostatistics, University of Washington, Seattle, Washington. 6. Departments of Medicine and Radiology, Johns Hopkins Hospital, Baltimore, Maryland. 7. Veterans Affairs Boston Healthcare System, Boston, Massachusetts; Department of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts; Division of Cardiology, Harvard Medical School, Boston, Massachusetts. 8. University of Washington, Department of Medicine, Seattle, Washington. 9. Department of Medicine, University of Utah, Salt Lake City, Utah. 10. Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Abstract
BACKGROUND: Circulating levels of endothelin-1 (ET1) are elevated in heart failure and predict poor prognosis. However, it is not clear whether ET1 elevation is an adaptive response, maladaptive response, or an epiphenomenon of heart failure. In this study, we evaluated the relationships between ET1, cardiac morphology, and incident heart failure or cardiovascular death in participants with no evidence of clinical cardiovascular disease at the time ET1 was measured. METHODS AND RESULTS: ET1 was measured in 1,361 participants in the Multi-Ethnic Study of Atherosclerosis Angiogenesis Sub-Study. As suggested by linear regression, participants with lower circulating ET1 levels tended to be older, non-white, more likely to have smoked heavily, and less likely to report intentional exercise. Participants with higher ET1 levels had smaller left ventricular end-diastolic volumes (8.9 ml smaller per log increase in ET1, 95% confidence interval 17.1-0.7, p = 0.03) with an increased left ventricular ejection fraction (2.8% per log increase in ET1, 95% confidence interval 0.5%-5.2%, p = 0.02). As suggested by Cox Proportional Hazards estimates, participants with higher ET1 levels had a lower risk for the composite outcome of heart failure or cardiovascular death in models that were unadjusted or had limited adjustment (p = 0.03 and p = 0.05, respectively). Lower risk for heart failure with higher ET1 levels could not be clearly shown in a model including health behaviors. CONCLUSIONS: These results suggest, but do not confirm, that elevated levels of circulating ET1 are associated with a more favorable cardiac phenotype. The relationship between ET1 and outcomes was not fully independent of one or more covariates.
BACKGROUND: Circulating levels of endothelin-1 (ET1) are elevated in heart failure and predict poor prognosis. However, it is not clear whether ET1 elevation is an adaptive response, maladaptive response, or an epiphenomenon of heart failure. In this study, we evaluated the relationships between ET1, cardiac morphology, and incident heart failure or cardiovascular death in participants with no evidence of clinical cardiovascular disease at the time ET1 was measured. METHODS AND RESULTS:ET1 was measured in 1,361 participants in the Multi-Ethnic Study of Atherosclerosis Angiogenesis Sub-Study. As suggested by linear regression, participants with lower circulating ET1 levels tended to be older, non-white, more likely to have smoked heavily, and less likely to report intentional exercise. Participants with higher ET1 levels had smaller left ventricular end-diastolic volumes (8.9 ml smaller per log increase in ET1, 95% confidence interval 17.1-0.7, p = 0.03) with an increased left ventricular ejection fraction (2.8% per log increase in ET1, 95% confidence interval 0.5%-5.2%, p = 0.02). As suggested by Cox Proportional Hazards estimates, participants with higher ET1 levels had a lower risk for the composite outcome of heart failure or cardiovascular death in models that were unadjusted or had limited adjustment (p = 0.03 and p = 0.05, respectively). Lower risk for heart failure with higher ET1 levels could not be clearly shown in a model including health behaviors. CONCLUSIONS: These results suggest, but do not confirm, that elevated levels of circulating ET1 are associated with a more favorable cardiac phenotype. The relationship between ET1 and outcomes was not fully independent of one or more covariates.
Authors: Steven M Kawut; R Graham Barr; João A C Lima; Amy Praestgaard; W Craig Johnson; Harjit Chahal; Kofo O Ogunyankin; Michael R Bristow; Jorge R Kizer; Harikrishna Tandri; David A Bluemke Journal: Circulation Date: 2012-08-29 Impact factor: 29.690
Authors: Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke Journal: AJR Am J Roentgenol Date: 2006-06 Impact factor: 3.959
Authors: Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: E J Kelso; R F Geraghty; B J McDermott; E R Trimble; D P Nicholls; B Silke Journal: Mol Cell Biochem Date: 1996 Apr 12-26 Impact factor: 3.396
Authors: Ioannis Smyrnias; Normann Goodwin; Dagmar Wachten; Jonas Skogestad; Jan Magnus Aronsen; Emma L Robinson; Kateryna Demydenko; Anne Segonds-Pichon; David Oxley; Sakthivel Sadayappan; Karin Sipido; Martin D Bootman; H Llewelyn Roderick Journal: J Mol Cell Cardiol Date: 2018-02-19 Impact factor: 5.000
Authors: Shoji Sanada; Daihiko Hakuno; Luke J Higgins; Eric R Schreiter; Andrew N J McKenzie; Richard T Lee Journal: J Clin Invest Date: 2007-05-10 Impact factor: 14.808
Authors: Chakradhari Inampudi; Daniel Silverman; Marc A Simon; Peter J Leary; Kavita Sharma; Brian A Houston; Jean-Luc Vachiéry; Francois Haddad; Ryan J Tedford Journal: Chest Date: 2021-08-12 Impact factor: 9.410
Authors: Krithika Krishnarao; Katelyn A Bruno; Damian N Di Florio; Brandy H Edenfield; Emily R Whelan; Logan P Macomb; Molly M McGuire; Anneliese R Hill; Jordan C Ray; Lauren F Cornell; Winston Tan; Xochiquetzal J Geiger; Gary R Salomon; Erika J Douglass; DeLisa Fairweather; Mohamad H Yamani Journal: J Clin Med Date: 2022-06-20 Impact factor: 4.964